Caseware UK (AP4) 2023.0.135 2023.0.135 2024-03-312024-03-3192023-04-01falseNo description of principal activity9falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 01524904 2023-04-01 2024-03-31 01524904 2022-04-01 2023-03-31 01524904 2024-03-31 01524904 2023-03-31 01524904 c:CompanySecretary1 2023-04-01 2024-03-31 01524904 c:Director1 2023-04-01 2024-03-31 01524904 c:RegisteredOffice 2023-04-01 2024-03-31 01524904 d:Buildings 2023-04-01 2024-03-31 01524904 d:Buildings 2024-03-31 01524904 d:Buildings 2023-03-31 01524904 d:Buildings d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 01524904 d:PlantMachinery 2023-04-01 2024-03-31 01524904 d:MotorVehicles 2023-04-01 2024-03-31 01524904 d:FurnitureFittings 2023-04-01 2024-03-31 01524904 d:OtherPropertyPlantEquipment 2023-04-01 2024-03-31 01524904 d:OtherPropertyPlantEquipment 2024-03-31 01524904 d:OtherPropertyPlantEquipment 2023-03-31 01524904 d:OtherPropertyPlantEquipment d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 01524904 d:OwnedOrFreeholdAssets 2023-04-01 2024-03-31 01524904 d:CurrentFinancialInstruments 2024-03-31 01524904 d:CurrentFinancialInstruments 2023-03-31 01524904 d:CurrentFinancialInstruments d:WithinOneYear 2024-03-31 01524904 d:CurrentFinancialInstruments d:WithinOneYear 2023-03-31 01524904 d:ShareCapital 2024-03-31 01524904 d:ShareCapital 2023-03-31 01524904 d:RetainedEarningsAccumulatedLosses 2024-03-31 01524904 d:RetainedEarningsAccumulatedLosses 2023-03-31 01524904 c:FRS102 2023-04-01 2024-03-31 01524904 c:AuditExempt-NoAccountantsReport 2023-04-01 2024-03-31 01524904 c:FullAccounts 2023-04-01 2024-03-31 01524904 c:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 01524904 6 2023-04-01 2024-03-31 01524904 d:AcceleratedTaxDepreciationDeferredTax 2024-03-31 01524904 d:AcceleratedTaxDepreciationDeferredTax 2023-03-31 iso4217:GBP xbrli:pure
Company registration number: 01524904







UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 MARCH 2024


CONSOLIDATED MEDICAL INDUSTRIES LIMITED






































img6171.png                        

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
COMPANY INFORMATION


Director
Mr A Hodgson 




Company secretary
Mrs C Hodgson



Registered number
01524904



Registered office
5 Rise Road

Ascot

Berkshire

SL5 0BH




Accountants
Menzies LLP
Chartered Accountants

Magna House

18-32 London Road

Staines-Upon-Thames

TW18 4BP





 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 



CONTENTS



Page
Statement of Financial Position
1 - 2
Notes to the Financial Statements
3 - 8


 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
REGISTERED NUMBER:01524904



STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2024

2024
2023
Note
£
£

Fixed assets
  

Tangible assets
 4 
134,188
159,702

  
134,188
159,702

Current assets
  

Stocks
  
212,000
186,088

Debtors: amounts falling due within one year
 6 
51,081
97,348

Cash at bank and in hand
  
96,079
76,293

  
359,160
359,729

Creditors: amounts falling due within one year
 7 
(192,605)
(201,400)

Net current assets
  
 
 
166,555
 
 
158,329

Total assets less current liabilities
  
300,743
318,031

Provisions for liabilities
  

Deferred tax
 8 
(17,986)
(13,153)

  
 
 
(17,986)
 
 
(13,153)

Net assets
  
282,757
304,878


Capital and reserves
  

Called up share capital 
  
2,000
2,000

Profit and loss account
  
280,757
302,878

  
282,757
304,878


Page 1

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
REGISTERED NUMBER:01524904


    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2024

The director considers that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr A Hodgson
Director

Date: 21 October 2024

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

1.


General information

Consolidated Medical Industries Limited is a private company limited by shares incorporated in England and Wales. The address of the principal place of business and the registered office is given in the company information page within these financial statements.
The company's financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured. Turnover is derived from the installation, repair, rental and sale of medical and pharmaceutical equipment and is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. 

 
2.3

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on both a reducing balance and straight-line basis.

Depreciation is provided on the following basis:

Land and buildings
-
20% straight-line
Plant and machinery
-
25% reducing balance
Motor vehicles
-
25% reducing balance
Fixtures and fittings
-
25% reducing balance
Other fixed assets
-
33% straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 3

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.4

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted company shares, whose market value can be reliably determined, are remeasured to market value at each reporting date. Gains and losses on remeasurement are recognised in the Statement of Income and Retained Earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

 
2.5

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.6

Operating leases: the company as lessee

Rentals paid under operating leases are charged to profit or loss on a straight-line basis over the lease term.

Benefits received and receivable as an incentive to sign an operating lease are recognised on a straight-line basis over the lease term, unless another systematic basis is representative of the time pattern of the lessee's benefit from the use of the leased asset.

 
2.7

Provisions for liabilities

Provisions are made where an event has taken place that gives the company a legal or constructive obligation that probably requires settlement by a transfer of economic benefit, and a reliable estimate can be made of the amount of the obligation.
Provisions are charged as an expense to profit or loss in the year that the company becomes aware of the obligation, and are measured at the best estimate at the reporting date of the expenditure required to settle the obligation, taking into account relevant risks and uncertainties.
When payments are eventually made, they are charged to the provision carried in the Statement of Financial Position.

Page 4

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

2.Accounting policies (continued)

 
2.8

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


3.


Employees

The average monthly number of employees, including directors, during the year was 9 (2023 - 9).

Page 5

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

4.


Tangible fixed assets





Land and buildings
Plant and machinery etc.
Total

£
£
£



Cost or valuation


At 1 April 2023
10,000
417,287
427,287


Additions
-
88,327
88,327


Disposals
-
(171,426)
(171,426)



At 31 March 2024

10,000
334,188
344,188



Depreciation


At 1 April 2023
10,000
257,585
267,585


Charge for the year on owned assets
-
57,684
57,684


Disposals
-
(115,269)
(115,269)



At 31 March 2024

10,000
200,000
210,000



Net book value



At 31 March 2024
-
134,188
134,188



At 31 March 2023
-
159,702
159,702

Page 6

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

5.


Fixed asset investments





Investments in subsidiary companies

£



Cost or valuation


At 1 April 2023
150,750



At 31 March 2024

150,750



Impairment


At 1 April 2023
150,750



At 31 March 2024

150,750



Net book value



At 31 March 2024
-



At 31 March 2023
-


6.


Debtors

2024
2023
£
£


Trade debtors
46,078
91,948

Other debtors
5,003
5,400

51,081
97,348



7.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
16,342
23,320

Corporation tax
-
3,890

Other taxation and social security
26,373
12,768

Other creditors
135,644
150,958

Accruals and deferred income
14,246
10,464

192,605
201,400


Page 7

 


CONSOLIDATED MEDICAL INDUSTRIES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024

8.


Deferred taxation




2024


£






At beginning of year
(13,153)


Charged to profit or loss
(4,833)



At end of year
(17,986)

The provision for deferred taxation is made up as follows:

2024
2023
£
£


Accelerated capital allowances
(17,986)
(13,153)

(17,986)
(13,153)

 
Page 8